Literature DB >> 2521397

Venous stenoses in dialysis shunts: treatment with self-expanding metallic stents.

R W Günther1, D Vorwerk, K Bohndorf, K C Klose, D Kistler, H Mann, H G Sieberth, A el-Din.   

Abstract

A flexible, self-expanding metallic endoprosthesis was employed for the treatment of venous outflow stenoses in four patients with a polytetrafluoroethylene shunt and two patients with a Brescia-Cimino shunt. The stenoses had led to shunt occlusion in five patients and to flow impairment in one. In the occluded shunts, thrombectomy and subsequent balloon angioplasty were performed in four patients, and percutaneous recanalization with angioplasty was performed in one. One shunt with decreasing flow was percutaneously dilated. Since the underlying stenoses recurred in four patients after 24 hours and did not respond sufficiently to angioplasty in two patients, up to four stents were placed in the venous segments. Thrombosis of the stents occurred in two patients after 24 hours and in one after 6 weeks and was successfully recanalized with thrombectomy in two. At 2-6 months follow-up, the stents and the shunts were patent in five patients. In three of these patients, intima hyperplasia, associated with narrowing of the stent lumen in two, was noted within 4 months after stent placement.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2521397     DOI: 10.1148/radiology.170.2.2521397

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  17 in total

Review 1.  Endovascular surgery for peripheral arterial occlusive disease. A critical review.

Authors:  S S Ahn; D Eton; W S Moore
Journal:  Ann Surg       Date:  1992-07       Impact factor: 12.969

2.  A comparison study of self-expandable stents vs balloon angioplasty alone in femoropopliteal artery occlusions.

Authors:  J Triller; B H Walpoth; P Stirnemann; F Mahler
Journal:  Cardiovasc Intervent Radiol       Date:  1992 Sep-Oct       Impact factor: 2.740

3.  Iliocaval stenosis and iliac venous thrombosis in retroperitoneal fibrosis: percutaneous treatment by use of hydrodynamic thrombectomy and stenting.

Authors:  D Vorwerk; R W Guenther; G Wendt; J Neuerburg; K Schürmann
Journal:  Cardiovasc Intervent Radiol       Date:  1996 Jan-Feb       Impact factor: 2.740

4.  Stenosis of a surgical portosystemic shunt--treatment with angioplasty and placement of a Wallstent.

Authors:  K A Hausegger; G E Klein; F Flückiger; W Planinz; R Wildling; H M Sternthal
Journal:  Cardiovasc Intervent Radiol       Date:  1993 Jul-Aug       Impact factor: 2.740

5.  Venous recanalization by metallic stents after failure of balloon angioplasty or surgery: four-year experience.

Authors:  G K Nazarian; W R Austin; S A Wegryn; H Bjarnason; D J Stackhouse; W R Castañeda-Zúñiga; D W Hunter
Journal:  Cardiovasc Intervent Radiol       Date:  1996 Jul-Aug       Impact factor: 2.740

6.  Central venous obstruction management.

Authors:  Sanjoy Kundu
Journal:  Semin Intervent Radiol       Date:  2009-06       Impact factor: 1.513

7.  Strecker stent in stenotic hemodialysis Brescia-Cimino arteriovenous fistulas.

Authors:  B Petar; I Tomislav; I Miodrag; A Snezana
Journal:  Cardiovasc Intervent Radiol       Date:  1992 Jul-Aug       Impact factor: 2.740

8.  Gianturco self-expanding stents: clinical experience in the vena cava and large veins.

Authors:  J D Irving; R F Dondelinger; J F Reidy; H Schild; R Dick; A Adam; M Maynar; C L Zollikofer
Journal:  Cardiovasc Intervent Radiol       Date:  1992 Sep-Oct       Impact factor: 2.740

9.  Use of the Wallstent in the venous system including hemodialysis-related stenoses.

Authors:  C L Zollikofer; F Antonucci; G Stuckmann; P Mattias; W F Brühlmann; E K Salomonowitz
Journal:  Cardiovasc Intervent Radiol       Date:  1992 Sep-Oct       Impact factor: 2.740

10.  Use of a cutting balloon for dilatation of a resistant venous stenosis of a hemodialysis fistula.

Authors:  D Vorwerk; R W Günther; K Schürmann; H G Sieberth
Journal:  Cardiovasc Intervent Radiol       Date:  1995 Jan-Feb       Impact factor: 2.740

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.